Firm
Transactions specialists at Paul Weiss are advising on the high-profile split of Kraft Heinz into two companies, while Skadden is also involved in the deal
Youngmin Park joins us for our ‘Five minutes with’ series to discuss learning languages, moonlighting as a drummer, and why late is better than never
The record-breaking $1.5 billion settlement between the AI company and book authors may not lead to rapid resolution of other cases, say copyright lawyers
Leaders at two Brazilian law firms outline strategies to adjust to trademark fee changes at Brazil's IP office while urging clients to apply before September 20
Sponsored
Sponsored
-
Sponsored by CASThe emerging trends and strategic approaches in intellectual property search and analytics are outlined in a CAS article that suggests how chemical industry stakeholders can strengthen patent programmes, empower R&D teams, and gain competitive insight -
Sponsored by Maiwald Intellectual PropertySenior Maiwald lawyers outline the strategy behind the firm’s recognition as EPO Proceedings Firm of the Year at the Managing IP EMEA Awards 2025 and discuss key developments in the European intellectual property space
-
Sponsored by Bugnion SpAVieri Canepele of Bugnion SpA examines a landmark Italian Supreme Court ruling on whether a patent co-owner may exploit a jointly owned invention without consent from fellow rights holders
-
Sponsored by Liu, Shen & AssociatesGuanyang Yao of Liu, Shen & Associates reviews several Chinese court rulings on standard-essential patent disputes, including Panasonic v Oppo, and the growing judicial focus on mediation and comparable licences over top-down rate setting
-
Sponsored by Wanhuida Intellectual PropertyWu Xiaohui of Wanhuida Intellectual Property examines how a recent CNIPA decision reinforces the need for a holistic inventive step assessment when evaluating pharmaceutical combination formulations involving active ingredients that are chemically reactive
-
Sponsored by Maiwald Intellectual PropertyAnnelie Wünsche of Maiwald Intellectual Property summarises the EU’s proposed update to the supplementary protection certificate system for medicinal products, highlighting key procedural shifts, the role of the EUIPO, and ongoing debate over the most suitable examining authority
